statement
The company's assertion that depth of IgG suppression matters in FcRn indications was clinically demonstrated.
A statement by 하나증권 제약/바이오 김선아. Statements are as reported by the cited publishers — not verified by DecisionGateway.
FcRn 적응증에서 IgG 억제의 깊이가 중요하다는 회사의 주장을 임상적으로 입증한 것
Discussion
Related claims
Rheumatoid arthritis may be a disease that requires suppression of pathogenic autoantibodies to a very deep level to confirm efficacy, consistent with J&J's nifocalimab failing in rheumatoid arthritis with a low ACPA antibody reduction rate.현대차증권 제약/바이오/의료기기 김현석 · statementGrowth defied RBI predictions.THnewsupdates · statementWhether approval for preparatory establishment is granted or the application is rejected, the FSC will issue a press release to explain publicly in addition to replying to the applicant.劉純斌 · commitmentInvestors awaited fresh signals from the Federal Reserve on its policy outlook.LiveMint · statementFollowing the halt of cutaneous lupus erythematosus development, a possibility of halting Sjögren's syndrome after completing phase 2 was mentioned; the pipeline value damage from indication discontinuations is judged limited.현대차증권 제약/바이오/의료기기 김현석 · statementRoivant CEO Matt Gline said on the conference call that they learned exciting, highly competitively valuable things and will say almost nothing about antibody reduction, but have a good amount of confidence going into phase 3.Matt Gline · statement